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Loss of SUFU Function in Familial Multiple Meningioma
Mervi Aavikko,1,2,8 Song-Ping Li,1,8 Silva Saarinen,1,2,8 Pia Alhopuro,1,3 Eevi Kaasinen,1,2
Ekaterina Morgunova,4 Yilong Li,1,2 Kari Vesanen,1,2 Miriam J. Smith,5 D. Gareth R. Evans,5
Minna Po¨yho¨nen,3 Anne Kiuru,6 Anssi Auvinen,7 Lauri A. Aaltonen,1,2 Jussi Taipale,1,4
and Pia Vahteristo1,2,*
Meningiomas are themost commonprimary tumors of theCNS and account for up to 30%of all CNS tumors. An increased risk ofmenin-
giomas has been associated with certain tumor-susceptibility syndromes, especially neurofibromatosis type II, but no gene defects pre-
disposing to isolated familial meningiomas have thus far been identified. Here, we report on a family of five meningioma-affected
siblings, four of whom have multiple tumors. No NF2 mutations were identified in the germline or tumors. We combined genome-
wide linkage analysis and exome sequencing, and we identified in suppressor of fused homolog (Drosophila), SUFU, a c.367C>T
(p.Arg123Cys)mutation segregatingwith themeningiomas in the family. The variationwas not present in healthy controls, and all seven
meningiomas analyzed displayed loss of the wild-type allele according to the classic two-hit model for tumor-suppressor genes. In silico
modeling predicted the variant to affect the tertiary structure of the protein, and functional analyses showed that the activity of the
altered SUFU was significantly reduced and therefore led to dysregulated hedgehog (Hh) signaling. SUFU is a known tumor-suppressor
gene previously associated with childhoodmedulloblastoma predisposition. Our genetic and functional analyses indicate that germline
mutations in SUFU also predispose to meningiomas, particularly to multiple meningiomas. It is possible that other genic mutations
resulting in aberrant activation of the Hh pathway might underlie meningioma predisposition in families with an unknown etiology.Meningiomas are the most common primary tumors of
the CNS and account for more than one-third of all
CNS tumors.1,2 Meningiomas originate from the arach-
noidal cells of the leptomeninges, and slowly growing
benign tumors comprise the great majority (95%) of
them. Depending on the location, meningiomas can cause
significant neurological deficits, but they can also be
asymptomatic. Imaging and autopsy studies have shown
that subclinical meningiomas occur in up to 3% of the
population.3,4 Although meningiomas are most com-
monly observed as solitary sporadic tumors, 1%–5% are
familial and fewer than 10% of individuals have multiple
lesions.5 The environmental risk factors for meningiomas,
except for ionizing radiation, are unclear.1 An increased
risk of meningiomas has been associated with tumor-
susceptibility syndromes such as neurofibromatosis type
II (NF2 [MIM 101000]), Cowden syndrome (CS [MIM
601728]), and Werner syndrome (WRN [MIM 277700]),
which are caused by mutations in NF2 (MIM 607379),
PTEN (MIM 601728), and RECQL2 (MIM 604611), respec-
tively. Also, a germline SMARCB1 (MIM 601607) mutation,
causing predisposition to schwannomatosis and rhabdoid
tumors, was recently identified in a family affected by
multiple cranial and spinal meningiomas and schwan-
nomas.6 Gene defects predisposing merely to meningi-
omas have not been previously reported.
Here, we report on a family of five meningioma-affected
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exome sequencing to identify the genetic predisposition
in this family. The index case (III-4, Figure 1) was referred
to genetic counseling after being operated on for meningi-
omas at different sites at the ages of 44, 48, and 59 years.
Multiple meningiomas had also been removed from
his three sisters: III-3 at the ages of 43 (single) and 54
(multiple) years, III-2 at the ages of 58 (single) and 64
(multiple) years, and III-1 at the age of 72 years (multiple).
His fourth sister (III-5) had been operated on for a single
meningioma when she was 60 years old. In addition to
meningiomas, a benign myoma had been removed from
III-3 at the age of 42, and III-5 was diagnosed with imma-
ture teratoma in both ovaries when she was 16 years old.
Other siblings in the family had been diagnosed with
lymphoma, colon adenocarcinoma, squamous cell carci-
noma of the facial skin (III-9), and facial basalioma
(III-11). Their cousin’s child (IV-1) had died ofmedulloblas-
toma at the age of 5 years. The father and mother of the
siblings (II-1 and II-2) had died of chronic lymphocytic
leukemia at the age of 58 years and of coronary thrombosis
at the age of 57 years, respectively. They had not been
examined for meningiomas. The index case (III-4) was
screened at the clinic for NF2mutations by direct sequenc-
ing andmultiplex ligation-dependent probe amplification,
but no mutations were detected. We also confirmed with
array comparative genomic hybridization (CGH [Human
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Figure 1. Pedigree of Family 1 with Five
Siblings with Intracranial Meningiomas
The ages at meningioma operations and
the c.367C>T (p.Arg123Cys) SUFU muta-
tion status of the individuals are shown.
A plus sign denotes a mutation, and a
minus sign denotes a wild-type allele. The
pedigree has been slightly modified for
confidentiality.Clara, CA]) and transcriptome analysis (GeneChip Human
Exon 1.0 ST Array, Affymetrix, Santa Clara, CA) that the
affected family members did not carry any larger chromo-
somal alterations at the NF2 locus and that their NF2
expression was not altered (fold change ¼ 0.99). The seven
available tumor samples from the affected individuals were
screened by direct sequencing for somatic NF2 mutations,
but none were identified.
Samples were obtained from four affected (III-1, III-2,
III-4, and III-5) and four other (III-10, a child of III-1, a child
of III-3, and a child of III-5) family members from Family 1
(Figure 1) after written informed consent was acquired.
Genomic DNAs were extracted from blood and were geno-
typed with Illumina’s Human610-Quad DNA analysis
BeadChips (Illumina, San Diego, CA). The hybridization
and scanning were performed according to the manufac-
turer’s protocol at the Finnish Institute for Molecular
Medicine (FIMM) Genome and Technology Centre. Geno-
type calling and quality analyses were done in BeadStudio
(Illumina), and genotypes with a GenCall score less than
0.15 were excluded as unreliable.
Nonparametric linkage analysis was performed with
Merlin7 (v.1.1.2) and for X chromosome with MINX.
Unlikely genotypes calculated with pedwipe in MERLIN
were removed before the analyses. Allele frequencies
were obtained from genotypes from members of family 1
and 265 healthy Finnish controls provided by the Nordic
Center of Excellence in Disease Genetics consortium. In
the analysis, the family members with multiple meningi-
omas (III-1, III-2, and III-4) were marked as affected, the
sibling with a single meningioma (III-5) and the three
children (children of III-1, III-3, and III-5) were marked asThe American Journal of Human Geneunknown, and the sibling with no
meningioma was marked as unaf-
fected (Figure 1). In total, 174 chro-
mosomal regions (1.3 Gb all together)
with positive LOD scores were identi-
fied (Table S1, available online).
To study the protein-coding vari-
ants residing in the linked regions,
we used the SureSelect Human All
Exon Kit (v.1) (Agilent) to capture
the germline exomes from III-1,
III-2, and III-4. Paired-end short read
sequences covering ~38 Mb of the
human genome were sequenced with
Illumina Genome Analyzer II atFIMM Genome Technology Centre. NextGENe (v.2.1)
software (Softgenetics, State College, PA) was used for
removing bad-quality reads, for mapping the reads to
human reference genome version NCBI37/Hg19, and for
calling the variants. All synonymous variants, known poly-
morphisms obtained from dbSNP (v.132), variants present
in 78 control exomes available from other projects in the
laboratory, and variants residing outside the linked regions
were excluded from further analyses.
After the exome data were combined with the linkage
data, only 20 candidate variants remained (Table S2). These
were further directly sequenced in all affected individuals
in family 1, and seven were shown to segregate with the
meningiomas in the family (Table S2). All seven variants
were then sequenced in a set of 188 Finnish blood donor
samples obtained through the Finnish Blood Transfusion
Service. Three of the variants were found in the controls
with a low frequency, and twowere present in the screened
unaffected siblings, from whom we had available DNA
(Table S3).
The two remaining variants were heterozygous missense
mutations c.1990A>G (p.Ser664Pro) (rs202247760) in
aminoadipate-semialdehyde synthase (AASS [MIM605113;
RefSeq accession number NM_005763.3]) and c.367C>T
(p.Arg123Cys) (rs202247756) in suppressor of fused
homolog (Drosophila), SUFU (MIM 607035; RefSeq
NM_016169.3). In silico analyses with PolyPhen28 and
SIFT9 predicted only the SUFU mutation to be damaging.
Both variants were sequenced in the seven available
formalin-fixed paraffin-embedded (FFPE) meningiomas
(one from III-1 and III-5 each, two from III-3, and
three from III-4) from the members of family 1. Loss oftics 91, 520–526, September 7, 2012 521
Figure 2. Loss of Heterozygosity and In Silico Modeling of the SUFU Mutation
(A) Heterozygous germline SUFUmutation c.367C>T (p.Arg123Cys) and loss of heterozygosity in ameningioma tumor tissue. The site of
the mutation is indicated by an arrow.
(B–D) Surface representation of the N-terminal part of SUFU modeled in COOT.12
(B) Cartoon of the secondary structure. The N- and C-terminal subdomains are marked, and Arg123 is represented by a ball-and-stick
model.
(C) Ribbon representation of the wild-type N-terminal part of SUFU. Secondary structure elements are labeled in accordance with
Merchant et al.11 Arg123 and residues involved in interactions are represented by ball-and-stick models. Dashed lines represent
hydrogen bonds and ionic contacts.
(D) The same orientation for the p.Arg123Cys altered SUFU. All contacts formed by Arg123 disappear, and loops are connected rather
weakly.heterozygosity (LOH) was detected at the site of the SUFU
mutation (Figure 2A) in all the tumors, whereas the AASS
variant site remained heterozygous in all of the seven
tumors. Because SUFU mutations are found in a fraction
of familial medulloblastomas, we screened the c.367C>T
mutation in a distant relative (IV-1, Figure 1) who had
died of medulloblastoma at 5 years of age. We utilized
DNA extracted from two different FFPE samples and per-
formed multiple sequencing reactions, but no mutations
were detected. SUFU mutations have also been observed522 The American Journal of Human Genetics 91, 520–526, Septembin a subset of skin tumors, and we acquired the FFPE blocks
of the facial-skin lesions from the two siblings (III-9 and
III-11). The sister with basalioma (III-11) did not harbor
the mutation, whereas the other sister with facial-skin
squamous cell carcinoma (III-9) did, but no LOH was
observed in the lesion.
To elucidate the properties of the p.Arg123Cys altered
SUFU, we modeled it with the program COOT12 (Fig-
ure 2B–2D). Arg123 resides inside the core of theN-terminal
subdomain of SUFU (Protein Data Bank entry 1M1L)13er 7, 2012
(Figure 2B), and it forms a very intensive network of
hydrogen bonds and ionic interactions with His89,
Asp182, Gln184, and Gln199 (Figure 2C). These residues
are central in the loop structures of the N-terminal subdo-
main of SUFU. An alteration in Arg123 might increase the
flexibility of the loops and affect the formation of proper
tertiary structure of the protein (Figure 2D).
SUFU is the major negative regulator of the Hh-signaling
pathway in humans.10,11,14 The pathway is essential in
embryogenesis, and in adult tissues, it is involved in the
control of stem cell proliferation.15 Its activation has also
been linked to the development ofmedulloblastomas, glio-
blastomas, and some basal cell carcinomas.15 The effect of
SUFU on Hh signaling is mainly mediated by its binding to
GLI1, GLI2, and GLI3 transcription factors. SUFU has also
been shown to prevent the nuclear transportation of
GLIs,16,17 as well as to promote their processing.
To study the effect of the observed SUFU variant on GLI
function in vitro, we generated the c.367C>T mutation in
a human SUFU cDNA construct cloned in a pCMV5_Myc
backbone vector (Clonetech, Mountain View, CA) by
utilizing the QuikChange Site-Directed mutagenesis kit
(Agilent). We directly sequenced the mutated clones to
ensure that only the correct mutation was created. The
primers used in the site-directed mutagenesis are listed in
Table S3. FuGENE HD (Roche, Basel, Switzerland) was
used for transfecting human rhabdomyosarcoma cells
(CRL-2061) with Myc-tagged wild-type or mutant SUFU
constructs, an Hh-pathway-specific reporter plasmid
‘‘SASAKI COOPER,’’18 and a control reporter Renilla lucif-
erase phRL-TK19 (Promega, Fitchburg, WI). CRL-2061 cells
are known to have constitutively activated Hh signaling as
a result of a 30-fold amplification of GLI1.20 Cells were
incubated for 2–3 days before the luciferase activity
was measured with the Dual-Reporter Luciferase system
(Promega). The luminescence was detected by the Digene
DCR-1 luminometer (Digene Diagnostics/QIAGEN, Hil-
den, Germany). The assays were conducted with and
without ShhN-conditioned medium in duplicate and
were repeated at least three times. We calculated the rela-
tive luciferase activity by dividing the firefly luciferase
counts by the Renilla luciferase counts. The same ex-
periments were also conducted in Sufu-deficient (Sufu/)
mouse embryonic fibroblasts (MEFs), and the results
from both cell lines indicated that compared with the
wild-type transfected cells, the altered SUFU had sig-
nificantly reduced ability to suppress GLI1 activity
(Figure 3A and 3B).
To study whether this was due to reduced binding of
altered SUFU to GLI, we studied the interaction of SUFU
and endogenous GLI1 by pull-down immunoblot analysis
in CRL-2061 cells. The cells were lysed and clarified by
centrifugation, and the supernatant was removed and
incubated with anti-GLI1 (H-300) agarose (Santa Cruz,
Santa Cruz, CA). The agarose beads were washed three
times with the lysis buffer without protease inhibitors
before the SDS sample buffer was added. The samplesThe Americanwere resolved on SDS-PAGE gels, transferred to polyvinyli-
dene-fluoride membranes, and incubated with the
following antibodies: goat anti-Myc HRP (ab1261, Abcam,
Cambridge, UK) and rabbit anti-Gli1 (ab92611, Abcam).
Goat anti-rabbit HRP was used as a secondary antibody.
The protein level of the p.Arg123Cys altered SUFU was
clearly reduced, and the altered protein bound less GLI1
than did the wild-type SUFU (Figure 3C).
To assess the effect of the p.Arg123Cys altered SUFU on
the subcellular localization of GLI1, we seeded Sufu/
MEFs on human-fibronectin-coated glass coverslips (BD,
Franklin Lakes, NJ) and transfected them with the Myc-
tagged wild-type and c.367C>T mutant SUFU expression
plasmids. Cells were incubated for 2 days in low-serum
medium with and without ShhN-conditioned medium
(Figure S1) and were stained as described previously.10
Specific anti-Myc, anti-Gli1 (ab49314, Abcam), Alexa-
594-conjugated anti-mouse, and Alexa-488-conjugated
anti-rabbit (Molecular Probes/Life Technologies, Carlsbad,
CA) antibodies were used for staining. This showed that
the altered SUFU was unable to relocalize GLI1 into the
cytoplasm (Figure 3D). Taken together, the functional
experiments indicate that the c.367C>T (p.Arg123Cys)
mutation in SUFU causes a partial loss of its repressor
activity and leads to aberrant activation of the Hh-
signaling pathway.
After identification of the SUFU c.367C>T (p.Arg123Cys)
mutation in family 1, the coding exons and exon-intron
boundaries of SUFU were sequenced in the DNA samples
from a total of 162 meningioma-affected individuals
(four Finnish individuals who had multiple meningiomas
and from whom NF2 mutations had been screened but
not identified, 77 Finnish simplex cases who had solitary
meningiomas and who were enrolled in the Interphone
case-control study,21 40 UK individuals with multiple
meningiomas,22 and 41 FFPE meningiomas collected
through the Finnish Cancer Registry [FCR] [Table 1]).
Informed consent was obtained from the Interphone study
subjects and from the four Finnish individuals with
multiple meningiomas. The use of 41 FCR-retrieved FFPE
samples was approved by the National Supervisory
Authority for Welfare and Health. The study was approved
by theMinistry of Social Affairs and Health in Finland, and
the usage of the samples was approved by the local ethics
review committees in Finland and the UK.
The primers used for blood and FFPE-tissue-derived
DNAs were designed with Primer3 (Table S3). Sequences
were analyzed manually and with Mutation Surveyor
software v.3.30 (SoftGenetics) with an NCBI reference
sequence (RefSeq NM_016169.3).
In total, 162 individuals with meningioma were
screened for additional SUFU mutations, but no patho-
genic variants were detected (Table S4). Of note, only 11
of the cases had a confirmed family history of the disease.
Furthermore, in family 1, four of the affected individuals
had been diagnosed with multiple tumors, which are
usually seen in fewer than 10% of the cases. The absenceJournal of Human Genetics 91, 520–526, September 7, 2012 523
Figure 3. The Effect of the p.Arg123Cys
Altered SUFU on Hedgehog Signaling
Activity
(A and B) The p.Arg123Cys altered SUFU
hasdecreasedactivity.Human rhabdomyo-
sarcoma cells (CRL-2061) and Sufu-defi-
cient (Sufu/) MEFs were transfected with
Myc-tagged wild-type (Myc-SUFUWT) or
altered (Myc-SUFUp.Arg123Cys) SUFU
constructs, an Hh-pathway-specific re-
porter, and a control reporter. The cells
were incubated with and without ShhN-
conditioned medium, and luciferase ac-
tivity was measured. Note that Myc-SUFU
suppresses Hh-pathway activity in both
human and mouse cell lines. *p < 0.05
compared with Myc-hSUFUWT (statistical
analysis was done with a t test). Error bars
indicate one standard deviation (duplicate
samples).
(C) The p.Arg123Cys altered SUFU binds
less GLI1 than does the wild-type SUFU.
CRL-2061 cell lysates used in luciferase
reporter assay were subjected to pull-
down immunoblot analysis (IP: GLI1;
WB: Myc and GLI1). In the top panel,
Myc-SUFU is pulled down with antibodies
against GLI1. Input of GLI1 and Myc-
tagged SUFU constructs is presented in
the middle and bottom panels, respec-
tively. Quantification of GLI1 binding rela-
tive to the Myc-SUFU protein level is
shown below the panel (quantitative
protein analysis was performed with the
Single Dimensional Electrophoretic Gel
Analysis program from the ImageJ software
package v.1.46g).
(D) Subcellular localization of p.Arg123Cys
altered SUFU in Sufu/ MEFs. Note
that the Gli1 nuclear localization was not
affected by the human SUFU mutant
(Myc-SUFUp.Arg123Cys) compared with
the wild-type SUFU (Myc-SUFUWT), as
indicated by arrows.of additional mutation-positive individuals might indicate
the very specific nature of the mutation—which provides
a ‘‘just right’’ level of SUFU dysfunction—and the resulting
small mutational target.
Mutations in SUFU predispose to childhood medullo-
blastomas, and somatic mutations have been observed
in medulloblastomas, as well as in a small subset of basal
cell skin cancers.23 A splice-site mutation has also been
reported in a family affected by basal cell nevus syn-
drome (BCNS [MIM 109400]) without the presence of
medulloblastomas.24 The germline SUFU mutations have
been predominantly truncating, and the tumors have
typically shown loss of the wild-type allele, indicating
that SUFU is a tumor suppressor. This notion has been
validated in knockout mice experiments.14,25 In contrast
to the previously reported truncating mutations, the
mutation identified in the meningioma-affected family
is a missense change converting arginine to cysteine.
Functional analyses indicate that the activity of the
altered protein is significantly reduced but not com-
pletely lost. Because SUFU is known to regulate Hh524 The American Journal of Human Genetics 91, 520–526, Septembsignaling in a concentration-dependent manner,16 we
hypothesize that the remaining activity of the altered
protein might explain the phenotypic difference between
aggressive childhood medulloblastomas and meningi-
omas. This, however, remains to be validated in further
studies.
SUFU is located in chromosomal region 10q24.32. The
long arm of chromosome 10 is frequently deleted in
meningiomas, especially in tumors with anaplastic, atyp-
ical, and malignant morphology. This deleted region
contains various known tumor-suppressor genes, among
which are PTEN and SUFU. Bostro¨m et al. (1998) studied
chromosome arm 10q in glioblastomas and meningiomas
and found PTEN to be mutated and deleted in a subset of
gliomas but not in meningiomas, suggesting that PTEN
is not the major tumor-suppressor gene at 10q in meningi-
omas.26 Of note, Laurendeau et al. (2010) showed that
23 of 32 (72%) genes in the Hh-signaling pathway were
differentially expressed in human meningiomas com-
pared to normal tissue, suggesting an important role for
Hh-pathway activation in meningiomas.27 A germlineer 7, 2012
Table 1. Meningioma Cases and Healthy Controls Used in the Study
Description of the Cases and Controls Number of Cases Family History of Meningiomas Lymphocyte DNA FFPE Tumor-Tissue DNA
Family 1, meningioma cases 5 yes 4 7
Family 1, other family members 11 yes 11 2
Finnish meningioma cases recruited
from the Interphone studya
77 not determined 77 0
Finnish multiple-meningioma casesb 4 no 4 0
UK multiple-meningioma casesb 35 no 35 0
Familialc UK meningioma cases 5 yes 5 0
Healthy blood donors 181 not determined 181 0
Meningioma Cases Identified from the Finnish Cancer Registry
Familialc Finnish meningioma cases 6 yes 1 5
Putatively familial meningioma casesd 20 possibly 0 20
Meningioma cases from the same
geographical region as family 1
6 not determined 0 6
Early-onset (%35 years) meningioma
cases
9 not determined 0 9
The following abbreviation is used: FFPE, formalin-fixed paraffin-embedded.
aINTERPHONE Study Group; Bethke et al.21
bThese cases have been screened for NF2 mutations, but no mutations were detected.
cDefined as R two first-degree relatives with meningioma.
dCollected on the basis of the family name at birth and birth municipality through a search into the Finnish Cancer Registry.mutation in PTCH1 (MIM 601309), another key player in
Hh signaling, has also been reported in an individual
with BCNS with multiple basal cell carcinoma and menin-
gioma.28
Meningiomas are common tumors, and a subset of them
displays familial aggregation. In some familial cases, the
genetic predisposition is caused by an inherited syndrome,
and the individuals display other syndromic manifesta-
tions as well. In other familial cases, however, the pre-
disposing factor remains unclear, particularly if additional
clinical signs pointing toward a well-characterized syn-
drome are lacking. Here, we report on a germline SUFU
c.367C>T (p.Arg123Cys) mutation segregating with the
meningiomas in a family of five affected siblings. Themuta-
tion was absent from the healthy controls, and all available
tumors from the family displayed clear loss of the wild-type
allele. We also showed that the altered protein’s ability to
suppress Hh signaling was significantly reduced. This
suggests that SUFU mutations predispose to meningiomas
in addition to medulloblastomas. Additional mutations
were not detected in other meningioma cases studied,
and this intuitively interesting finding thus awaits confir-
mation in an independent material. It is also possible that
other genic mutations resulting in an abnormal activation
of theHhpathwaymight underlie themeningioma suscep-
tibility in some families with yet unknown etiology.Supplemental Data
Supplemental Data include one figure and four tables and can be
found with this article online at http://www.cell.com/AJHG.The AmericanAcknowledgments
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